Absci Q3 revenue misses estimates, net loss widens on R&D spends

Absci Q3 revenue misses estimates, net loss widens on R&D spends


Overview

  • U.S. biopharma company's Q3 revenue fell and missed analyst expectations

  • Net loss widened in Q3 as R&D expenses rose for internal programs

  • Company appointed Gerry Muhle as Chief Commercial Officer to build commercial infrastructure


Outlook

  • Absci expects 13-week interim proof-of-concept data for ABS-201 in PHL in Dec 2026

  • Company anticipates full 26-week proof-of-concept data for ABS-201 in early 2027

  • Absci plans to initiate Phase 2 STORYLINE trial for ABS-201 in endometriosis in mid-2027


Result Drivers

  • R&D SPENDING - Co said higher research and development expenses were mainly due to advancement of internal programs, including direct costs for ABS-201 clinical and nonclinical development

  • SG&A COSTS - Selling, general, and administrative expenses rose due to increased stock-based compensation


Company press release: ID:nGNXHxDmV


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$304,000

$727,130 (8 Analysts)

Q3 Net Loss

$33.30 mln

Q3 Loss Per Basic Share

$0.19

Q3 Operating Expenses

$35.30 mln

Q3 Operating Income

-$34.99 mln

Q3 Pretax Loss

$33.28 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Absci Corp is $15.00, about 48.2% above its November 11 closing price of $10.12


Reuters Recommended Reads

  • Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise

  • Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs

  • Nov 10 - Palisade Bio Q3 loss widens on higher R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbSci

See all news